Kevin B. Bacon, Ph.D.
Founder, CSO and Head of Research & Development

Dr. Bacon founded Actimis as a spin-off from Bayer Yakuhin Ltd.’s Respiratory Research Department in Kyoto, Japan. Dr. Bacon was most recently Vice President for Respiratory diseases research with line and matrix management responsibilities for respiratory small molecule therapeutic development company-wide. Dr. Bacon was also involved in establishing and managing major corporate collaborations and partnerships (Oxford Glycosciences, Entelos, Lion, Galapagos Genomics, Inc., as well as numerous academic and Institutional collaborations). Prior to joining Bayer in 1999, Dr. Bacon was Associate Director of Immunology at Neurocrine Biosciences, Inc., in San Diego, and from 1994 to 1997 a Visiting Scientist at the DNAX Institute for Molecular Biology (a subsidiary of Schering Plough), in Palo Alto. Dr. Bacon received his B.Sc. and Ph.D. in Pharmacology from the University of London (King’s College and United Medical and Dental Schools of Guy’s and St. Thomas’, respectively) and following post-doctoral studies, joined the Glaxo Institute for Molecular Biology (now Serono) in Geneva, Switzerland as a staff scientist focused on inflammation research. Dr. Bacon has published over 100 original manuscripts, book chapters and reviews and has been a regular contributor of original research to the field of chemokine biology since its inception with specific interest, and pioneering many studies, in the signaling mechanisms of these molecules and their biological roles in cells of the immune system.

Stefen A. Boehme, Ph.D.
Director of Immunology

Dr. Stefen Boehme joined Actimis in March 2005 as Director of Immunology, and brings to Actimis 10 years of experience in drug development within the pharmaceutical industry. Most recently, he conducted research at the La Jolla Institute of Molecular Medicine focused upon inflammatory diseases such as asthma. Prior to that, Dr. Boehme was a Senior Scientist at Genicon Sciences, responsible for applying RLS (resonance light scattering) technology towards facilitating the drug discovery cascade. From 1995 to 2003, Dr. Boehme held numerous positions at Neurocrine Biosciences, where he was involved in developing both small molecule and biological therapeutics for diseases such as asthma, multiple sclerosis, type I diabetes and obesity. His post-doctoral training was obtained at the National Institutes of Health in both the National Institute of Allergy and Infectious Diseases and the National Cancer Institute. Dr. Boehme received his B.S. from Muhlenberg College and a Ph.D. from the University of Florida School of Medicine.

Tai Wei Ly, Ph.D.
Associate Director of Chemistry

Dr. Ly joined Actimis upon its inception and is Associate Director of Chemistry. Most recently, he was a group leader in Bayer Yakuhin Ltd.’s department of chemistry charged with the management of chemistry support for early research projects in inflammation and urology. Previous to that, Dr. Ly held the position of lab head and project leader with responsibilities in the directing of chemistry activities for various projects in the Respiratory Research Department. Dr. Ly received his B.Sc. and Ph.D. in Chemistry from the University of Alberta in Canada and further honed his skills in organic synthesis with a post-doctoral fellowship in the Institute of Chemistry at Academia Sinica, Taiwan. Scientifically, Dr. Ly is interested in the total synthesis of natural products and the development of synthetic methodologies. Dr. Ly is the author of several peer-reviewed scientific articles.